GRAIL is trading at $150.47, up 5.03%, as optimism continues after an FDA advisory panel endorsed Galleri’s potential benefits. - The endorsement is a step toward, but not a guarantee of, FDA approval; Reuters reported the FDA could rule in the coming months. - On October 2, UBS raised its price target to $175 from $105 and maintained a Buy rating. - No separate October 5 company announcement was identified; moderate broad-market gains do not clearly explain the move.